Did Cerus beat or miss consensus estimates last quarter?

What is Cerus's gross profit margin?

What factors drove the changes in Cerus's revenue and profit?

What guidance did Cerus's management provide for the next earnings period?

What is the market's earnings forecast for Cerus next quarter?

What were the key takeaways from Cerus's earnings call?

What does Cerus do and what are its main business segments?

What is the revenue and EPS growth rate for Cerus year over year?

- **Record Revenue Growth**: 2025 total revenue $233.8M (+16% YoY), driven by U.S. platelets and EMEA expansion. 
- **Strategic Partnerships**: BCA agreement targets 30% U.S. market penetration; Germany's $30M platelet opportunity via INITIATE study. 
- **IFC Acceleration**: 80% revenue growth to $16.7M, shifting to 100% kit sales by 2026. 
- **Financial Health**: Positive non-GAAP EBITDA ($9.5M annual), but gross margin pressured by tariffs. 
- **RBC Regulatory Progress**: European CE Mark expected 2027; U.S. Phase III study results Q4 2026. 


**【Management Opening Remarks】**
- CEO Obi Greenman highlighted 2025 milestones: 3 million INTERCEPT-treated blood components sold, benefiting ~600,000 patients globally. 
- Launched INT200 device in Europe with positive customer feedback; U.S. PMA submission expected mid-2026.
- Red blood cell (RBC) regulatory progress: European notified body review complete, transfer to ANSM for review; U.S. Phase III RedeS study enrollment complete, top-line results expected Q4 2026.

**【Commercial Highlights (Vivek Jayaraman)】**
- **U.S. Platelet Franchise**: Mid-60s market share; BCA group purchasing agreement (effective Jan 2026) targets 30% penetration among BCA's 50% U.S. blood supply. 
- **EMEA Growth**: 25% Q4 product revenue growth (FX-adjusted), driven by platelet and plasma sales. Germany's $30M annual platelet opportunity via INITIATE study enrollment. 
- **IFC Momentum**: 80% full-year revenue growth (to $16.7M); 70% of Q4 sales in kit format, targeting 100% kit sales by end-2026. BCA partnership to expand IFC manufacturing. 

**【Financial Results (Kevin Green)】**
- **2025 Revenue**: $233.8M (16% YoY growth), with product revenue up 14% to $202.8M. 
- **Product Gross Margin**: 51.5% (Q4) vs. 53.9% prior year, pressured by tariffs and inflation. 
- **Non-GAAP EBITDA**: $9.5M annual (2nd consecutive year positive). 
- **2026 Guidance**: Product revenue $224-228M (9-11% growth), IFC $20-22M (20-30% growth). 

**【Q&A Highlights】**
- **BCA Agreement**: Leverages BCA's supply chain and education channels; 150+ attendees at first joint webinar. 
- **Germany RBC Study**: Enrollment ongoing in 2026, potential revenue contribution from 2027. 
- **Cash Flow**: 2026 operating cash flow expected to remain stable, with inventory investments to support growth. 
- **RBC Regulatory**: CE Mark in Europe likely 2027; U.S. PMA submission contingent on RedeS study results. 


Cerus Corporation(CERS)-20260303-2025 Q4 Earnings call transcript

- **Revenue milestone**: Q3 product revenue hits $52.7 million (+15% YoY), driven by U.S. platelet adoption (mid-60% penetration) and IFC kit sales shift.
- **Strategic shift success**: IFC revenue up 70% YoY to $3.9 million, with 70%+ kit sales vs. <25% in Q3 2024.
- **Margin improvement path**: Kit-based IFC sales to blood centers expected to stabilize gross margins amid FX and tariff pressures.
- **Operational strength**: 6th consecutive quarter of positive adj. EBITDA ($5 million Q3); $78.5 million cash balance.
- **International growth**: Germany study (INITIATE) underway; INT200 installations accelerating in Europe.

**【CEO Opening Remarks】**
- Q3 2025 product revenue reached $52.7 million, up 15% YoY, driven by U.S. platelet adoption (mid-60% penetration) and IFC kit sales shift to blood centers.
- INTERCEPT RBC Phase III trial enrollment completed; CE Mark delayed 6 months due to regulatory transition in Europe.
- German Red Cross study (INITIATE) underway, with AK Blut recommending pathogen reduction for platelets.
- INT200 LED illuminator launched in Europe, with U.S. PMA submission planned for mid-2026.

**【COO Commercial Update】**
- U.S. platelet franchise growth supported by 70%+ kit sales vs. <25% in Q3 2024; IFC revenue up 70% YoY to $3.9 million.
- INT200 installations accelerating in Q4; EMEA platelet sales +21% YoY, driven by Middle East and Germany.
- Clinicians highlight IFC cost savings ($1,200 per surgical procedure) and reduced waste vs. cryoprecipitate.

**【CFO Financial Review】**
- Full year 2025 product revenue guidance raised to $202-204 million (prev. $200-203M), with IFC sales $16-17 million.
- Q3 non-GAAP adj. EBITDA $5 million (6th consecutive quarter positive); GAAP net loss ~$0.
- Product gross margin 53.4% (vs. 56.9% YoY), pressured by tariffs, inflation, and IFC production costs.
- Cash balance $78.5 million; operating cash flow $1.9 million Q3, net cash used $1.4 million YTD.

**【Q&A Highlights】**
- **Gross margin stabilization**: Kit-based IFC sales to blood centers expected to improve margins; FX and tariffs remain headwinds.
- **Supply chain confidence**: Blood centers report no IFC supply constraints; 20+ million INTERCEPT-treated components transfused globally.
- **OpEx trends**: R&D expenses up due to INT200 PMA costs; SG&A leverage improving with revenue growth.
- **2026 outlook**: IFC >90% kit-based; Germany and INT200 driving international expansion; RBC CE Mark decision in H2 2026.

Cerus Corporation (CERS) Q3 2025 Earnings Call Transcript

- **Revenue Record**: Q2 product revenue $52.4M (+16% YoY), full year guidance raised to $200-203M.
- **IFC Growth**: IFC sales guidance raised to $16-18M, driven by U.S. adoption and global supply stability.
- **INT200 Launch**: Europe deployment underway, approved in France/Switzerland with positive customer feedback.
- **Red Cell Expansion**: CE Mark submission covers all transfusion indications, targeting 2026 approval.
- **Financial Strength**: 5th consecutive quarter of positive EBITDA ($935K), cash balance $78M supporting growth.

**【CEO Opening Remarks】**
- Q2 product revenue reached $52.4 million, up 16% YoY, driven by IFC and platelet sales growth.
- Full year 2025 product revenue guidance raised to $200-203 million (prev: $194-200M), with IFC sales expected to reach $16-18 million (prev: $12-15M).
- INT200 Illuminator launched in Europe, approved in France and Switzerland, with positive feedback from customers.
- Red blood cell program CE Mark submission expanded to all patient indications, targeting 2026 approval.

**【COO Commercial Highlights】**
- U.S. IFC adoption accelerating, with hospitals increasing 100% pathogen-inactivated platelet inventory.
- EMEA growth driven by Middle Eastern platelet sales and plasma business expansion in Flanders and Madrid.
- INT200 deployment underway, with potential regulatory shift in Germany for bacterial testing requirements.
- Clinical advocacy for IFC in cardiac surgery and postpartum hemorrhage showcased at major conferences.

**【CFO Financial Summary】**
- Q2 product gross profit $29 million (55.2% margin), stable vs. prior year despite FX and cost pressures.
- Operating expenses $40.1 million (18.9% R&D, 21.2% SG&A), up 18% YoY due to COGS adjustments and government contracts.
- Fifth consecutive quarter of positive non-GAAP EBITDA ($935,000) vs. $779,000 prior year.
- Cash balance $78 million, with working capital investments to support growth.

**【Q&A Highlights】**
- Revenue cadence: Q3 may flatten due to summer holidays, Q4 expected to rebound strongly.
- EU red blood cell opportunity: Expanded CE Mark removes HP restrictions, opening all transfusion indications.
- IFC supply/demand: Backlog cleared, strong pipeline of new and existing hospital orders.
- OpEx trends: Government contract growth and cost adjustments driving R&D/S&G increases, with leverage expected in H2.

Cerus Corporation (CERS) Q2 2025 Earnings Call Transcript

- **Revenue Beat**: Q1 2025 product revenue $43.2M (+13% YoY), ahead of guidance midpoint.
- **INT200 Success**: CE Mark received early, with 7/8 IFC partners now BLA-approved for cross-state distribution.
- **Red Blood Cell Milestone**: Updated CE Mark submission filed; Phase 3 study nearing completion.
- **Profitability**: Q1 non-GAAP EBITDA positive ($157K) vs. -$2.7M YoY; 2025 positive EBITDA target reaffirmed.
- **Market Expansion**: Discussions with 5M+ annual platelet unit markets in Middle East, Germany, and China.

**【CEO Opening Remarks】**
- Q1 2025 product revenue: $43.2M (+13% YoY), driven by North American platelet kits and IFC demand.
- INT200 LED device CE Mark received ahead of schedule, with positive customer feedback.
- Full-year product revenue guidance reaffirmed: $194M-$200M, including $12M-$15M from IFC.
- Non-GAAP adjusted EBITDA positive for Q1 ($157K) and expected to remain positive for 2025.

**【COO Commercial Highlights】**
- North America: 22% YoY growth in platelet kits, IFC sales up 63% YoY to $3M.
- Europe: EMEA product revenue down 1% (non-GAAP), but France maintains 100% platelet market share.
- Global expansion: Discussions with blood centers in new geographies (e.g., Middle East, Germany) for 5M+ annual platelet units.
- IFC production ramping with 7/8 partners holding BLAs, enabling cross-state distribution.

**【CFO Financial Review】**
- Gross margin: 58.8% (Q1 2025 vs. 55.4% Q1 2024), driven by inventory adjustments.
- Operating expenses: $36.9M (+7.6% YoY), with higher R&D for INT200 and cost of living adjustments.
- Net loss: $7.7M (-20% YoY), with improving cash flow ($80.9M on hand).
- Tariff impact: Expected to keep gross margin >50%, despite potential headwinds.

**【Q&A Key Takeaways】**
1. **North America Growth**: US platelet share expansion and IFC adoption (50+ hospitals) driving 22% YoY growth.
2. **INT200 Strategy**: Device to enable new market entries (e.g., Middle East, China) and US PMA submission in 2026.
3. **Red Blood Cell Program**: CE Mark submission underway; Phase 3 RedeS study nearing completion (500+ patients enrolled).
4. **Financial Resilience**: Positive EBITDA momentum despite macroeconomic uncertainty; $80M+ cash on hand for growth investments.

Cerus (CERS)-1 May 25-2025 Q1 Earnings call transcript

- **2024 Financial Milestone**: Achieved $5.7M positive adjusted EBITDA, up from -$10.7M in 2023.
- **Revenue Growth**: Product revenue up 15% to $180.3M, driven by 42% IFC growth and global platelet expansion.
- **2025 Outlook**: 8-11% revenue growth, mid-50s gross margins, and positive cash flow continuity.
- **Market Expansion**: China NMPA approval in 2025, Brazil government approval pending, and 100% adoption in Canada.
- **Key Risks**: FX headwinds (~20bps in Q4), IFC production scale, and North America inventory normalization.

**【CEO Opening Remarks】**
- Cerus achieved positive adjusted EBITDA of $5.7 million in 2024, marking a significant improvement from -$10.7 million in 2023.
- Product revenue grew 15% year-over-year to $180.3 million, driven by strong demand in the U.S. IFC business and global platelet franchise.
- For 2025, the company expects product revenue growth of 8% to 11%, with a focus on maintaining mid-50s product gross margins and improving operational efficiency.

**【COO Business Highlights】**
- IFC sales grew 42% in 2024 to $9.2 million, with Q4 sales up 30% year-over-year to $3 million, driven by BLA approvals enabling cross-state distribution.
- Canadian Blood Services achieved 100% adoption of INTERCEPT platelet kits, stabilizing the core platelet market.
- China: NMPA approval expected in 2025, with provincial reimbursement process estimated to take 12 months post-approval.
- Brazil: Government approval process ongoing, with potential rollout following approval.

**【CFO Financial Review】**
- 2024 GAAP net loss narrowed 44% to $20.9 million, with Q4 net loss of $2.5 million.
- Product gross margin remained stable at 55.2%, though Q4 dipped to 53.9% due to FX, freight costs, and discard rates.
- Operating expenses decreased 8% to $134.8 million, with R&D down 13% and SG&A relatively flat.
- Positive operating cash flow of $11.4 million for the year, up from -$43.2 million in 2023.

**【Q&A Key Takeaways】**
- **IFC Supply & Demand**: Production ramp-up aligns with demand, with no supply constraints expected in 2025.
- **China Market Access**: NMPA approval in 2025, with revenue contribution delayed until provincial reimbursement completes.
- **Gross Margin Drivers**: FX headwinds (~20bps in Q4) and IFC production scale impact 2025 margins, but mid-50s target remains.
- **SG&A Growth**: Modest increase due to inflation, but leverage expected from revenue growth.
- **North America Platelet Growth**: Q4 slowdown due to inventory normalization, with long-term share capture intact.
- **Brazil Commercialization**: Government approval anticipated later in 2025, with rollout dependent on approval timing.

Actual											-0.1	-0.09	-0.08	-0.09	-0.1	-0.09	-0.07	-0.05	-0.07	-0.05	-0.05	-0.08	-0.09	-0.07	-0.04	-0.01	-0.05	-0.03	-0.02	-0.01	-0.04	-0.03	0	-0.01
Forecast											-0.11	-0.11	-0.1	-0.0871	-0.1	-0.0975	-0.095	-0.0775	-0.0825	-0.07	-0.0575	-0.0556	-0.0833	-0.0575	-0.0533	-0.0275	-0.0479	-0.042	-0.032	-0.012	-0.04	-0.0275	-0.0275	-0.0075
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+9.09%	+18.18%	+20.00%	-3.33%	0.00%	+7.69%	+26.32%	+35.48%	+15.15%	+28.57%	+13.04%	-43.88%	-8.04%	-21.74%	+24.95%	+63.64%	-4.38%	+28.57%	+37.50%	+16.67%	0.00%	-9.09%	+100.00%	-33.33%

CERS

CERS fundamentals

CERS Q4 2025 Earnings

Earnings Call

You can ask Aime

CERS

CERS fundamentals

CERS Q4 2025 Earnings

Earnings Call

CERS Earnings Call Summary for Q4/20254:30 PM on Mar 2, 2026

CERS Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

CERS Earnings Call Summary for Q2/20254:30 PM on Aug 5, 2025

CERS Earnings Call Summary for Q1/20254:30 PM on May 1, 2025

CERS Earnings Call Summary for Q4/20244:30 PM on Feb 20, 2025

You can ask Aime